CLINICAL RESEARCH: CORONARY ARTERY DISEASE
Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy
Christopher P. Cannon, MD*,
Benjamin A. Steinberg, BA,
Sabina A. Murphy, MPH,
Jessica L. Mega, MD and
Eugene Braunwald, MD
Thrombolysis In Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts.
Manuscript received January 23, 2006;
revised manuscript received March 30, 2006,
accepted April 4, 2006.
* Reprint requests and correspondence: Dr. Christopher P. Cannon, TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis Street, Boston, Massachusetts 02115. (Email: cpcannon{at}partners.org).
OBJECTIVES: The purpose of this study was to conduct a meta-analysis that compares the reduction of cardiovascular outcomes with high-dose statin therapy versus standard dosing.
BACKGROUND: Debate exists regarding the merit of more intensive lipid lowering with high-dose statin therapy as compared with standard-dose therapy.
METHODS: We searched PubMed and article references for randomized controlled trials of intensive versus standard-dose statin therapy enrolling more than 1,000 patients with either stable coronary heart disease or acute coronary syndromes. Four trials were identified: the TNT (Treating to New Targets) and the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid-Lowering) trials involved patients with stable cardiovascular disease, and the PROVE IT–TIMI-22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction-22) and A-to-Z (Aggrastat-to-Zocor) trials involved patients with acute coronary syndromes. We carried out a meta-analysis of the relative odds on the basis of a fixed-effects model using the Mantel-Haenszel method for the major outcomes of death and cardiovascular events.
RESULTS: A total of 27,548 patients were enrolled in the 4 large trials. The combined analysis yielded a significant 16% odds reduction in coronary death or myocardial infarction (p < 0.00001), as well as a significant 16% odds reduction of coronary death or any cardiovascular event (p < 0.00001). No difference was observed in total or non-cardiovascular mortality, but a trend toward decreased cardiovascular mortality (odds reduction 12%, p = 0.054) was observed.
CONCLUSIONS: Intensive lipid lowering with high-dose statin therapy provides a significant benefit over standard-dose therapy for preventing predominantly non-fatal cardiovascular events.
|
Abbreviations and Acronyms
| | A-to-Z = Aggrastat-to-Zocor trial | | ACS = acute coronary syndrome | | CI = confidence interval | | CTT = Cholesterol Treatment Trialists | | IDEAL = Incremental Decrease in End Points Through Aggressive Lipid-Lowering trial | | LDL = low-density lipoprotein | | MI = myocardial infarction | | NCEP = National Cholesterol Education Program | | OR = odds ratio | | PROVE IT–TIMI-22 = Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction-22 trial | | TNT = Treating to New Targets trial |
|
This article has been cited by other articles:
|
|
|
|
 
T. Y. Tang, S. P.S. Howarth, S. R. Miller, M. J. Graves, A. J. Patterson, J.-M. U-King-Im, Z. Y. Li, S. R. Walsh, A. P. Brown, P. J. Kirkpatrick, et al.
The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study: Evaluation Using Ultrasmall Superparamagnetic Iron Oxide-Enhanced Magnetic Resonance Imaging in Carotid Disease
J. Am. Coll. Cardiol.,
June 2, 2009;
53(22):
2039 - 2050.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Schaefer, J. A. Gleason, and M. L. Dansinger
Dietary Fructose and Glucose Differentially Affect Lipid and Glucose Homeostasis
J. Nutr.,
June 1, 2009;
139(6):
1257S - 1262S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Tobis and A. Perlowski
Atheroma volume by intravascular ultrasound as a surrogate for clinical end points.
J. Am. Coll. Cardiol.,
March 31, 2009;
53(13):
1116 - 1118.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Heart Protection Study Collaborative Group
Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels
Circ Cardiovasc Qual Outcomes,
March 1, 2009;
2(2):
65 - 72.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Robinson, S. Wang, B. J. Smith, and T. A. Jacobson
Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk.
J. Am. Coll. Cardiol.,
January 27, 2009;
53(4):
316 - 322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M Ridker, E. Danielson, F. A.H. Fonseca, J. Genest, A. M. Gotto Jr., J. J.P. Kastelein, W. Koenig, P. Libby, A. J. Lorenzatti, J. G. MacFadyen, et al.
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
N. Engl. J. Med.,
November 20, 2008;
359(21):
2195 - 2207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. R. Giraldez, R. P. Giugliano, S. Mohanavelu, S. A. Murphy, C. H. McCabe, C. P. Cannon, and E. Braunwald
Baseline Low-Density Lipoprotein Cholesterol Is an Important Predictor of the Benefit of Intensive Lipid-Lowering Therapy: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Analysis
J. Am. Coll. Cardiol.,
September 9, 2008;
52(11):
914 - 920.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
The SEARCH Collaborative Group
SLCO1B1 Variants and Statin-Induced Myopathy -- A Genomewide Study
N. Engl. J. Med.,
August 21, 2008;
359(8):
789 - 799.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Y. Chan, K. W. Mahaffey, L. J. Sun, K. S. Pieper, H. D. White, P. E. Aylward, J. J. Ferguson, R. M. Califf, and M. T. Roe
Prevalence, Predictors, and Impact of Conservative Medical Management for Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Who Have Angiographically Documented Significant Coronary Disease
J. Am. Coll. Cardiol. Intv.,
August 1, 2008;
1(4):
369 - 378.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Barnett, G. Hitman, E. Hughes, and K. Khunti
New Perspectives on the Management of Type 2 Diabetes: Report of symposia at the Royal College of Physicians, London, 16 April 2008 and Hilton Hotel, Coventry, 14 May 2008
The British Journal of Diabetes & Vascular Disease,
July 1, 2008;
8(4):
198 - 205.
[PDF]
|
|
|
|
|
|
|
J Armitage
Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia
Heart,
May 1, 2008;
94(5):
643 - 645.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. D. Peterson and T. Y. Wang
The Great Debate of 2008--How Low to Go in Preventive Cardiology?
JAMA,
April 9, 2008;
299(14):
1718 - 1720.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Josan MD, S. R. Majumdar MD MPH, and F. A. McAlister MD MSc
The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials
Can. Med. Assoc. J.,
February 26, 2008;
178(5):
576 - 584.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Grundy
Promise of Low-Density Lipoprotein-Lowering Therapy for Primary and Secondary Prevention
Circulation,
January 29, 2008;
117(4):
569 - 573.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G Hackam
The ankle brachial index independently predicted all-cause mortality in high-risk patients with peripheral arterial disease
Evid. Based Med.,
December 1, 2007;
12(6):
187 - 187.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Behfar and A. Terzic
Cardioprotective repair through stem cell-based cardiopoiesis
J Appl Physiol,
October 1, 2007;
103(4):
1438 - 1440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al.
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
J. Am. Coll. Cardiol.,
August 14, 2007;
50(7):
e1 - e157.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Leeper, R. Ardehali, E. M. deGoma, and P. A. Heidenreich
Statin Use in Patients With Extremely Low Low-Density Lipoprotein Levels Is Associated With Improved Survival
Circulation,
August 7, 2007;
116(6):
613 - 618.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Afilalo, A. A Majdan, and M. J Eisenberg
Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials
Heart,
August 1, 2007;
93(8):
914 - 921.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kaul
Cost-effectiveness of high-dose atorvastatin compared with usual-dose simvastatin: less than IDEAL?
Eur. Heart J.,
June 6, 2007;
(2007)
ehm168v1.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E Anderson, K. Brismar, and T. Ivert
Only a minority of patients referred for elective coronary artery bypass surgery have risk factors diagnosed and treated according to established guidelines
Diabetes and Vascular Disease Research,
June 1, 2007;
4(2):
112 - 116.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. G. Hackam and J. D. Spence
Combining Multiple Approaches for the Secondary Prevention of Vascular Events After Stroke: A Quantitative Modeling Study
Stroke,
June 1, 2007;
38(6):
1881 - 1885.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Garg and V. Simha
Update on Dyslipidemia
J. Clin. Endocrinol. Metab.,
May 1, 2007;
92(5):
1581 - 1589.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Sanz, P. R. Moreno, and V. Fuster
The Year in Atherothrombosis
J. Am. Coll. Cardiol.,
April 24, 2007;
49(16):
1740 - 1749.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. V. Deshpande, H. M. Mardikar, and D. Deo
A Call for Development of Comprehensive Therapy for Dyslipidemia
J. Am. Coll. Cardiol.,
April 3, 2007;
49(13):
1502 - 1502.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. Cannon and E. Braunwald
Reply
J. Am. Coll. Cardiol.,
April 3, 2007;
49(13):
1502 - 1503.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L K. Newby
Review: high dose statins reduce risk of non-fatal cardiovascular events more than standard dose statins
Evid. Based Med.,
April 1, 2007;
12(2):
42 - 42.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. N. Patel, M. H. Shishehbor, and D. L. Bhatt
A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis
Eur. Heart J.,
March 2, 2007;
28(6):
664 - 672.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Ovbiagele and J. L. Saver
Intensive Statin Therapy After Stroke or Transient Ischemic Attack: A Sparcling Success?
Stroke,
March 1, 2007;
38(3):
1110 - 1112.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Statins work better at higher doses in patients with coronary heart disease
BMJ,
September 9, 2006;
333(7567):
.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Intensive Statin Therapy Prevents Nonfatal Cardiovascular Events
Journal Watch Cardiology,
August 30, 2006;
2006(830):
3 - 3.
[Full Text]
|
|
|
|
